Methods
Eligibility Criteria
Information Sources and Literature Search
Outcome Measures
Study Selection
Data Collection Process and Data Extraction
Risk of Bias in Individual Studies
Effect Size Calculation and Quantitative Data Synthesis
Risk of Bias Across Studies
Moderator Analysis
Results
Study Selection
Characteristics of Studies, Interventions, and Participants
References | Total Na | Treatment group(s)(N)/average dose/dosage regimen | Control group (N) | PLA lead-in (w) | Duration (w) |
---|---|---|---|---|---|
Antidepressants
| |||||
Black (2004) | 10 | Bupropion (10) 100–300 mg/d/flexible | None | 0 | 8 |
Black et al. (2007a) | 39 | Burpopion (18) 324 mg/d/flexible | PLA (21) | 0 | 12 |
Black et al. (2007b) | 19 | Escitalopram (19) 10–30 mg/d/flexible | None | 0 | 10 |
Blanco et al. (2002) | 32 | Fluvoxamine (15) 100 mg/d (2 weeks) 200 mg/d (rest of trial)/fixed | PLA (17) | 0 | 24 |
Dannon et al. (2005a) | 20 | (1) Topiramate (12) 200 mg/d/fixed | (2) Fluvoxamine (8)c 200 mg/d/fixed | 0 | 12 |
Dannon et al. (2005b) | 12 | Bupropion (12) 300–450 mg/d/flexible | None | 0 | 12 |
Dannon et al. (2005c) | 25 | (1) Bupropion (12)c 300–450 mg/d/flexible | (2) Naltrexone (13) 100–150 mg/d/flexible | 0 | 12 |
Egorov (2017) | 20 | Agomelatine (20) 25–50 mg/d/flexible | None | 0 | 8 |
Grant et al. (2003) | 71 | Paroxetine (34) 10–60 mg/d/flexible | PLA (37) | 1 | 16 |
Grant and Potenza (2006) | 13 | Escitalopram (13) 10–30 mg/d/flexible | None | 1 | 11 |
Hollander et al. (1998) | 10 | Fluvoxamine (10) 220 mg/d/flexible | None | 8 | 8 |
Hollander et al. (2000) | 10 | Fluvoxamine (4) 195 mg/d/flexible | PLA (6) | 1 | 16 |
Kim et al. (2002) | 45 | Paroxetine (23) 51.7 mg/d/flexible | PLA (22) | 1 | 8 |
Myrseth et al. (2011) | 15 | (1) Escitalopram (15)d 5–10 mg/d/flexible for 8 w, followed by (2) Escitalopram + 8 sessions CBT for 8 w (3) CBT + MI (15)e | None | 0 | 8 |
Pallanti et al. (2002a) | 12 | Nefazodone (12) 345.83 mg/d/flexible | None | 0 | 8 |
Ravindran and Telner (2006) | 19 | (1) Paroxetine (5) 10–60 mg/d/flexible (2) Paroxetine 10–60 mg/d/flexible + 12 sessions CBT (7) | PLA + 12 sessions CBT (7)f | 0 | 16 |
Saiz-Ruiz et al. (2005) | 60 | Sertraline (31) 95 mg/d/flexible | PLA (29) | 0 | 24 |
Zimmerman et al. (2002) | 15 | Citalopram (15) 34.7 mg/d/flexible | None | 0 | 12 |
Opioid antagonists
| |||||
Dannon et al. (2005c) | 25 | (1) Bupropion (12) 300–450 mg/d/flexible | (2) Naltrexone (13)g 100–150 mg/d/flexible | 0 | 12 |
Grant et al. (2006) | 73 | (1) Nalmefene 25 mg/d (40) (2) Nalmefene 50 mg/d (29)h (3) Nalmefene 100 mg/d (33)/fixed | PLA (44) | 0 | 16 |
77 | Naltrexone 50, 100, 150 mg/i (58)/fixed | PLA (19) | 1 | 17 | |
Grant et al. (2010b) | 128 | Nalmefene 20 mg Nalmefene 40 mg (57)h/fixed | PLA (71) | 1 | 3 |
Kim and Grant (2001) | 17 | Naltrexone (17) 157 mg/d/flexible | None | 0 | 6 |
Kim et al. (2001) | 45 | Naltrexone (20) 187.5 mg/d/flexible | PLA (25) | 1 | 11 |
Kovanen et al. (2016) | 101 | Naltrexone/flexible 50 mg in case of craving +3 sessions psychosocial support (50) | PLA + 3 sessions psychosocial support (51) | 0 | 20 |
Lahti et al. (2010) | 39 | Naltrexone/flexible 50 mg in case of craving + 1 MI + booklet (39) | None | 0 | 16 |
Toneatto et al. (2009) | 52 | Naltrexone 100 mg/d/flexible + 7 sessions CBT (27) | PLA + 7 sessions CBT (25) | 0 | 10 |
Mood stabilizers
| |||||
Berlin et al. (2013) | 42 | Topiramate (20) 222.5 mg/d/flexible | PLA (22) | 0 | 14 |
Black et al. (2008) | 8 | Carbamazepine (8) 675 mg/d/flexible | None | 0 | 10 |
Dannon et al. (2005a) | 20 | (1) Topiramate (12)k 200 mg/d/fixed | (2) Fluvoxamine (8) 200 mg/d/fixed | 0 | 12 |
De Brito et al. (2017) | 30 | Topiramate 180.7 mg/d/flexible +4 sessions CR (15) | PLA + 4 sessions CR (15) | 0 | 12 |
Fong et al. (2008) | 21 | Olanzapine (9) 2.5–10 mg/d/fixed | PLA (12) | 0 | 7 |
Hollander et al. (2005a) | 29 | Lithium (12) 1.150 mg/d/flexible | PLA (17) | 0 | 10 |
McElroy et al. (2008) | 42 | Olanzapine (21) 2.5–15 mg/d/flexible | PLA (21) | 1 | 12 |
Pallanti et al. (2002b) | 42 | (1) Lithium (23) 795.6 mg/d/flexible | (2) Valproate (19) 873.7 mg/d/flexible | 0 | 14 |
Other medications
| |||||
Black et al. (2011) | 19 | Acamprosate (19) 1.998 mg/d/fixed | None | 0 | 8 |
Grant et al. (2007) | 27 | N-Acetylcystein (27) 600–1.800 mg/d/flexible | None | 0 | 8 |
Grant et al. (2010a) | 29 | Memantine (29) 10–30 mg/d/flexible | None | 0 | 10 |
Grant et al. (2013) | 22 | Tolcapone (22) 100–300 mg/d/flexible | None | 0 | 8 |
Grant et al. (2014a) | 22 | Ecopipam/flexible (22) 50 mg in case of craving | None | 1 | 6 |
Grant et al. (2014b) | 28 | N-Acetylcystein 1.200–3.000 mg/d/ flexible +AART + ID + MI (13) | PLA + AART + ID +MI (15) | 0 | 12 |
References | FU (m) | Outcomes (assessment) | Gambling type/MD/A (+/−)b/% Males | Data analysis | EPHPP |
---|---|---|---|---|---|
Antidepressants
| |||||
Black (2004) | None | GS (PG-YBOCS) | NA/− ≤ 50% | CO | 3 |
Black et al. (2007a) | None | GS (PG-YBOCS; G-SAS) FR (min/w) FL (money/w) | NA/− > 50% | ITT | 3 |
Black et al. (2007b) | None | GS (PG-YBOCS) FR (min/w) FL (money/w) | NA/− > 50% | CO | 3 |
Blanco et al. (2002) | None | FR (h/w) FL (money/w) | NA/− > 50% | ITT | 3 |
Dannon et al. (2005a) | None | GS (PG-YBOCS) | NA/− > 50% | CO | 2 |
Dannon et al. (2005b) | None | GS (PG-CGI) | NA/− > 50% | CO | 3 |
Dannon et al. (2005c) | None | GS (PG-YBOCS) | NA/− > 50% | CO | 2 |
Egorov (2017) | None | GS (PG-YBOCS) FR (h/w) FL (money/w) | NA/+ > 50% | CO | 3 |
Grant et al. (2003) | None | GS (PG-YBOCS; G-SAS) | NA/− > 50% | ITT | 2 |
Grant and Potenza (2006) | None | GS (PG-YBOCS; G-SAS) | E/+ > 50% | ITT | 3 |
Hollander et al. (1998) | None | GS (PG-YBOCS) | Other/+ > 50% | CO | 3 |
Hollander et al. (2000) | None | GS (PG-YBOCS) | Other/− > 50% | CO | 2 |
Kim et al. (2002) | None | GS (G-SAS) | E/− ≤ 50% | ITT | 2 |
Myrseth et al. (2011) | 6 | GS (G-SAS) FL (money/w) | E/− > 50% | ITT | 3 |
Pallanti et al. (2002a) | None | GS (PG-YBOCS) FR (episodes/w; min./episodes) FL (money/w) | E/− > 50% | CO | 3 |
Ravindran and Telner (2006) | None | GS (PG-YBOCS; G-SAS) | NA/− > 50% | CO | 3 |
Saiz-Ruiz et al. (2005) | None | GS (SOGS) FR (gambling activity/w) FL (money/w) | NA/− > 50% | ITT | 2 |
Zimmerman et al. (2002) | None | GS (PG-YBOCS) FR (days/w) FL (money/w) | E/+ > 50% | CO | 3 |
Opioid antagonists
| |||||
Dannon et al. (2005c) | None | GS (PG-YBOCS) | NA/− > 50% | CO | 2 |
Grant et al. (2006) | None | GS (PG-YBOCS; G-SAS) | NA/− > 50% | CO | 3 |
None | GS (PG-YBOCS; G-SAS) | E/− ≤ 50% | ITT | 2 | |
Grant et al. (2010b) | None | GS (PG-YBOCS; G-SASj) | NA/− > 50% | CO | 3 |
Kim and Grant (2001) | None | GS (G-SAS) FR (episodes/w) FL (money/w) | NA/− ≤ 50% | ITT | 3 |
Kim et al. (2001) | None | GS (G-SAS) FR (episodes/w) | NA/− ≤ 50% | CO | 2 |
Kovanen et al. (2016) | None | GS (PG-YBOCS) FR (days/w) FL (highest daily expenditure/w) | E/− > 50% | ITT | 2 |
Lahti et al. (2010) | None | GS (PG-YBOCS) | NA/− > 50% | ITT | 3 |
Toneatto et al. (2009) | 12 | FR (gambling activities/w) FL (money/w) | Other/− > 50% | ITT | 2 |
Mood stabilizers
| |||||
Berlin et al. (2013) | None | GS (PG-YBOCS; G-SAS) | NA/− ≤ 50% | ITT | 2 |
Black et al. (2008) | None | GS (PG-YBOCS; G-SAS) FR (min/w) FL (money/w) | NA/− > 50% | CO | 3 |
Dannon et al. (2005a) | None | GS (PG-YBOCS) | NA/− > 50% | CO | 2 |
De Brito et al. (2017) | None | GS (PG-YBOCS; G-SAS) FR (h/m) FL (money/m) | E/− > 50% | CO | 2 |
Fong et al. (2008) | None | GS (PG-CGI) FR (days/w) FL (money/d) | E/− > 50% | CO | 2 |
Hollander et al. (2005a) | None | GS (PG-YBOCS) FR (episodes/w; min/episodes) FL (money/w) | NA/+ > 50% | CO | 1 |
McElroy et al. (2008) | None | GS (PG-YBOCS) FR (episodes/w; h/w) | NA/− ≤ 50% | ITT | 2 |
Pallanti et al. (2002b) | None | GS (PG-YBOCS) | E/− > 50% | ITT | 2 |
Other medications
| |||||
Black et al. (2011) | None | GS (PG-YBOCS; G-SAS) FR (min/w; episodes/w) FL (money/w) | NA/− ≤ 50% | CO | 3 |
Grant et al. (2007) | None | GS (PG-YBOCS; G-SAS) FL (money/w) | E/− > 50% | ITT | 3 |
Grant et al. (2010a) | None | GS (PG-YBOCS; G-SAS) FR (h/w) FL (money/w) | E/− ≤ 50% | ITT | 3 |
Grant et al. (2013) | None | GS (PG-YBOCS; G-SAS) | NA/− ≤ 50% | CO | 3 |
Grant et al. (2014a) | None | GS (PG-YBOCS; G-SAS) | NA/− > 50% | CO | 3 |
Grant et al. (2014b) | 3 | GS (PG-YBOCS) | NA/− > 50% | ITT | 2 |
Risk of Bias Within Studies
Synthesis of Results and Risk of Bias Across Studies
Outcome | Effect | Within-group study designs | Controlled study designs | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
k
|
g
| 95% CI |
z
|
p
|
I
2
| FS N |
k
|
g
| 95% CI |
z
|
p
|
I
2
| FS N | ||
Overall | |||||||||||||||
GS | Post | 33 | 1.35 | [1.14; 1.57] | 12.35 | < 0.001 | 83.96*** | 7166 | 17 | 0.41 | [0.22; 0.59] | 4.27 | < 0.001 | 44.48* | 131 |
FU | 3 | 1.63 | [0.81; 2.44] | 3.92 | < 0.001 | 83.64** | 65 | 1 | 1.31 | [0.35; 1.91] | 2.84 | < 0.01 | 0.00 | –b | |
FR | Post | 13 | 1.22 | [0.85; 1.59] | 6.43 | < 0.001 | 87.53*** | 899 | 9 | 0.11 | [− 0.08; 0.30] | 1.12 | 0.264 | 0.00 | –a |
FU | 1 | 0.47 | [0.11; 0.82] | 2.59 | < 0.05 | 0.00 | –b | 1 | − 0.03 | [− 0.65; 0.59] | − 0.10 | 0.924 | 0.00 | –b | |
FL | Post | 15 | 0.80 | [0.52; 1.07] | 5.66 | < 0.001 | 85.13*** | 685 | 8 | 0.22 | [0.02; 0.43] | 2.15 | < 0.05 | 0.00 | 2 |
FU | 2 | 0.27 | [0.01; 0.52] | 2.07 | < 0.05 | 0.00 | –b | 1 | − 0.18 | [− 0.81; 0.44] | − 0.58 | 0.565 | 0.00 | –b | |
AD | |||||||||||||||
GS | Post | 15 | 1.32 | [0.91; 1.72] | 6.41 | < 0.001 | 87.94*** | 988 | 6 | 0.37 | [− 0.04; 0.77] | 1.76 | 0.078 | 63.08* | –a |
FR | Post | 5 | 1.71 | [0.91; 2.51] | 4.18 | < 0.001 | 90.14*** | 200 | 3 | 0.05 | [− 0.28; 0.39] | 0.31 | 0.759 | 0.00 | –a |
FL | Post | 6 | 1.24 | [0.47; 2.01] | 3.16 | < 0.01 | 93.57*** | 159 | 3 | 0.09 | [− 0.24; 0.43] | 0.55 | 0.586 | 0.00 | –a |
OA | |||||||||||||||
GS | Post | 5 | 1.41 | [1.00; 1.82] | 6.74 | < 0.001 | 82.70*** | 341 | 5 | 0.46 | [0.26; 0.66] | 4.55 | < 0.001 | 0.00 | 24 |
FR | Post | 3 | 0.81 | [0.19; 1.44] | 2.55 | < 0.05 | 88.82*** | 33 | 2 | − 0.001 | [− 0.32; 0.31] | − 0.009 | 0.993 | 0.00 | –b |
FL | Post | 3 | 0.55 | [0.25; 0.85] | 3.57 | < 0.001 | 59.53 | 22 | 2 | 0.15 | [− 0.28; 0.58] | 0.67 | 0.505 | 41.79 | –b |
MST | |||||||||||||||
GS | Post | 7 | 1.23 | [0.88; 1.58] | 6.97 | < 0.001 | 65.87** | 254 | 5 | 0.53 | [0.06; 0.99] | 2.23 | < 0.05 | 54.35 | 10 |
FR | Post | 3 | 1.18 | [0.83; 1.54] | 6.54 | < 0.001 | 0.00 | 29 | 4 | 0.31 | [− 0.04; 0.66] | 1.73 | 0.084 | 0.00 | –a |
FL | Post | 3 | 0.64 | [0.35; 0.93] | 4.29 | < 0.001 | 0.00 | 13 | 3 | 0.53 | [0.05; 1.02] | 2.18 | < 0.05 | 16.40 | 2 |
Other | |||||||||||||||
GS | Post | 6 | 1.62 | [1.16; 2.07] | 7.01 | < 0.001 | 78.56*** | 336 | 1 | − 0.36 | [− 1.09; 0.36] | − 0.98 | 0.327 | 0.00 | –b |
FR | Post | 2 | 0.85 | [0.38; 1.32] | 3.54 | < 0.001 | 60.98 | –b | NA | ||||||
FL | Post | 3 | 0.55 | [0.28; 0.81] | 4.04 | < 0.001 | 43.08 | 20 | NA |
Effect Sizes of Within-Group Study Designs at Posttreatment and Follow-Up
Effect Sizes of Controlled Study Designs at Posttreatment and Follow-Up
Moderator Analyses
Moderator | Outcome variable | Within-group study designs | Controlled study designs | ||
---|---|---|---|---|---|
Qbet
|
p(Q)
|
Qbet
|
p(Q)
| ||
Treatment (pharmacological, combined) | GS | 3.34 | 0.067 | 1.39 | 0.239 |
FR | 3.35 | 0.067 | 0.00 | 0.938 | |
FL | 1.66 | 0.197 | 0.52 | 0.469 | |
Medication class (AD, OA, MST, other) | GS | 1.59 | 0.663 | 3.32 | 0.345 |
FR | 4.31 | 0.230 | 1.83 | 0.400 | |
FL | 3.24 | 0.357 | 2.62 | 0.270 | |
AD type (SSRI/SNDRI, NDRI, agomelatine) | GS | 20.97 | < 0.001 | 0.93 | 0.335 |
FR | 4.80 | < 0.05 | 0.04 | 0.850 | |
FL | 11.09 | < 0.01 | 0.05 | 0.825 | |
OA type (naltrexone, nalmefene) | GS | 0.00 | 1.00 | 0.01 | 0.917 |
FR | 0.00 | 1.00 | 0.00 | 1.00 | |
FL | 0.00 | 1.00 | 0.00 | 1.00 | |
MST type (carbamazepine, lithium, olanzapine, topiramate, valproate) | GS | 0.65 | 0.958 | 8.21 | < 0.05 |
FR | 0.04 | 0.982 | 2.16 | 0.339 | |
FL | 0.11 | 0.946 | 2.39 | 0.302 | |
Other type (acamprosate, ecopipam, memantine, N-acetylcysteine, tolcapone) | GS | 0.25 | 0.993 | 0.00 | 1.00 |
FR | 2.56 | 0.109 | NA | NA | |
FL | 3.51 | 0.173 | NA | NA | |
Dosage regimen (fixed, flexible) | GS | 5.01 | < 0.05 | 0.18 | 0.671 |
FR | 0.32 | 0.572 | 0.11 | 0.742 | |
FL | 1.04 | 0.309 | 0.17 | 0.679 | |
Data analysisa (CO, ITT) | GS | 0.009 | 0.923 | 1.86 | 0.172 |
FR | 0.03 | 0.873 | 1.67 | 0.102 | |
FL | 0.11 | 0.741 | 2.50 | 0.114 | |
Placebo lead-in (none, 1 week, 8 weeks) | GS | 3.31 | 0.191 | 0.04 | 0.850 |
FR | 1.88 | 0.171 | 0.34 | 0.559 | |
FL | 0.82 | 0.366 | 1.79 | 0.181 | |
Type of gamblingb (electronic, other) | GS | 3.38 | 0.066 | 0.40 | 0.527 |
FR | 0.89 | 0.346 | 0.59 | 0.442 | |
FL | 1.38 | 0.241 | 1.77 | 0.183 | |
EPHPP (1, 2, 3) | GS | 1.99 | 0.158 | 0.25 | 0.619 |
FR | 0.09 | 0.764 | 0.22 | 0.642 | |
FL | 0.00 | 0.972 | 0.61 | 0.434 | |
Comorbid MD/A (Included, Excluded) | GS | 1.88 | 0.171 | 6.98 | < 0.01 |
FR | 0.53 | 0.468 | 0.06 | 0.811 | |
FL | 1.68 | 0.195 | 0.66 | 0.415 | |
% Males (≤ 50%, > 50%) | GS | 0.46 | 0.498 | 1.15 | 0.284 |
AD | 0.09 | 0.759 | 10.18 | < 0.01 | |
FR | 0.09 | 0.770 | 0.01 | 0.905 | |
FL | 0.55 | 0.458 | 0.00 | 1.00 |